The Power of Target Product Profiles: Three Case Studies
In the biopharma industry, the Target Product Profile (TPP) is a critical tool…
Unlocking Success: The Power of Target Product Profiles
In the ever-evolving biopharma landscape, success hinges not just on innovation…
Unfinished Business on the Glass Ceiling
Reflecting on my career and the significant societal and technological shifts…
Governance: The Glue to a Successful Launch
At the core of every successful launch lies a meticulously crafted plan, a…
Three Big Mistakes
Over the past 20 years, The NemetzGroup has been involved in the launch of more than 50 different drugs and has had input into the strategic…
What’s the Latest?
There are many ways we introduce ourselves to make an impact and grab the attention of our audience. In our line of work, that might be what your…
Gen Z Advice for Seasoned Boomers
“Gen Z professionals have a low tolerance for inefficiency and are not going to allow their boomer bosses to remain selective luddites.” That’s how…
Find Your Own Light
It’s no secret that the last few years have been hard on just about everyone. COVID, climate change, political strife in the US and around the world……
The Truth about Teams
When it comes to team performance and adherence to “best practices,” what works on paper or in a teambuilding workshop and what actually occurs are…
Running the Biopharma Marathon
When I moved to Boston over thirty years ago, I had never even heard of the Boston Marathon. I grew up in the Midwest and moved to the West Coast for…
Rare Diseases: Shaping Biopharma’s Future from the Past
We just completed Rare Disease month. With that in mind, Sue has asked me to step in for today’s e-conversation, as this topic is very much a part of…
“Rare Disease” Is More Than Just a Day
You might think it odd for me to begin this month’s e-conversation with a quote from a Supreme Court justice. However, this insight has stuck with me…
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness — but the illness was the primary focus. In recent years, much has…
